Speakers

Expand/Collapse

Kimberly Aardalen
Scientific Technical Leader
Novartis Institutes for Biomedical Research

Thomas Schürpf
Senior Director, Tumor Biology
Parthenon Therapeutics

Day Two

Thursday, July 15, 2021

3:45 pm | Breaking Down Barriers In Immune-Excluded Tumor Biology

Khalid Shah
Vice Chairman at BWH
Harvard Medical School

Day One

Wednesday, July 14, 2021

9:30 am | Translatability at a Glance: Combined Gene Edited & Engineered Cellular Therapies for Solid Tumors

Agnieszka Denslow
Associate Director
Pharmacology / Toxicology, Oncorus

Day Two

Thursday, July 15, 2021

8:30 am | Modelling Small Cell Lung Cancer in Preclinical Development of Synthetic Oncolytic Virus

Beatrice Wang
Associate Director
IGM Biosciences

Day One

Wednesday, July 14, 2021

8:30 am | Combination of a Multimeric Anti-DR5 IgM Antibody with Targeted Agents Induces Synergistic Tumor Cytotoxicity in Vitro & in Vivo

Frank Sun
Senior Principal Scientist, Oncology Pharmacology
Sanofi

Preclinical Track - Day 1 am

11:45 am | Humanized Mouse Model as a Translational Tool for Immunotherapy in Oncology

Jessica Haverkamp
Associate Director Macrophage Biology
BlueRock Therapeutics

Day One

Wednesday, July 14, 2021

4:30 pm | Chair’s Closing Remarks & End of Conference Day One

8:20 am | Chair’s Opening Remarks

Preclinical Track - Day 1 am

11:15 am | Panel Discussion: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification

Jingjing Jiang
Senior Director, Translational Research
Revolution Medicines

Translation Track - Day 1 am

11:45 am | Combination Therapy to Outsmart RASAddicted Cancer - Informing Clinical Strategy with Preclinical Modeling

Natalia Blanco
Associate Director, Immuno-Oncology
Morphic Therapeutics

Drug Discovery Track - Day 2 pm

1:15 pm | Treatment Modalities to Improve Response in Tumors Refractory to Standard Immunotherapy Approaches

Katie Grausam
Postdoctoral Scientist
Cedars Sinai

Day Two

Thursday, July 15, 2021

11:15 am | Weighing up Pros & Cons of Quick & Dirty Models Versus Slower Growing Models

3:15 pm | Panel Discussion - What Are the Advantages of 3D Models

Ludovic Bigot
Project Manager
Gustav Rousey

Drug Development Track - Day 2 pm

2:15 pm | Panel Discussion: Resistance Versus Sensitivity of the Drug Towards the Tumor

1:45 pm | MATCH-R: A Preclinical Platform of Resistant Models to Innovative Therapies • Highlighting the development of a panel

Marc Pelletier
Senior Principal Scientist
Novartis

Preclinical Track - Day 1 am

11:15 am | Panel Discussion: Utilizing RNA-Seq for Better Pre-Clinical Predictions & Patient Identification

Marc Zuckermann
Group Leader Preclinical Modeling
German Cancer Research Center (DKFZ)

Translation Track - Day 1 am

11:15 am | Targeting c-MET in Combination with Radiation is Effective in MET-Fusion Driven High- Grade Glioma

Johanna Lahdenranta
Director In Vivo Pharmacology
Bicycle Therapeutics

Drug Development Track - Day 2 pm

1:15 pm | Exploring Tumor Localized CD137 Agonism with Bicycle Tumor-Targeted Immune Cell Agonists (Bicycle TICAs®)

Juan Arriaga
Assistant Professor – Department of Oncological Sciences & Urology
Icahn School of Medicine at Mount Sinai

Day One

Wednesday, July 14, 2021

1:45 pm | Modeling Bone Metastasis of Prostate Cancer

Day Two

Thursday, July 15, 2021

3:15 pm | Panel Discussion - What Are the Advantages of 3D Models

Scott Boiko
Associate Director Translational Science
Forma Therapeutics

Day Two

Thursday, July 15, 2021

9:15 am | Roundtable: Outlining Model Validation & Establishing the Need for Standardization

Anita Seshire
Head Of Laboratory in Exploratory Cancer Research, Translational Innovation Platform Oncology- Immunooncology
Merck EMD Serono

Day One

Wednesday, July 14, 2021

3:30 pm | Developing Clinically Translatable Models that Accurately Represent Patient Metastasis

Day Two

Thursday, July 15, 2021

3:15 pm | Panel Discussion - What Are the Advantages of 3D Models

Tomasz Owczarek
Senior Staff Scientist
Regeneron

Drug Discovery Track - Day 2 pm

2:15 pm | Model Selection for Tumor Heterogeneity & TME

Soner Altiok
CSO
Nilogen Oncosystems

Jon Waterman-Smith
Vice President Of Marketing & Business Development
Nilogen Oncosystems

Jun Zhang
MD, PhD, Associate Professor
University of Kansas Medical Center, Medical Oncology

Javier Pineda
Bioinformatics Lead
Scientist.com

Day Two

Thursday, July 15, 2021

12:00 pm | The Disease Model Finder: An AI-Powered Platform to Enhance Disease Model Sourcing

Marco Campisi
Postdoctoral Research Fellow
Dana-Farber Cancer Institute

Day Two

Thursday, July 15, 2021

3:15 pm | Panel Discussion - What Are the Advantages of 3D Models

Drug Discovery Track - Day 2 pm

1:45 pm | Retaining the Tumor Immune Microenvironment Heterogeneity & Vascular Cross-talks in Ex-Vivo Microphysiological Models

Gareth Griffiths
CSO
Imagen Therapeutics

Day One

Wednesday, July 14, 2021

10:00 am | Patient-Derived Cell (PDC) Models as a Tool to Assess Cancer Therapeutic Efficacy Across the Drug Development Life Cycle

Senior Representative

Hera BioLabs

Day Two

Thursday, July 15, 2021

11:45 am | Orthotopic & Metastatic Xenograft Studies in the SRG Rat

Monika Buczek, PhD
Director
Business Development

Day Two

Thursday, July 15, 2021

10:00 am | Translating Preclinical Combinatorial Therapy Approaches in In Vitro & In Vivo Models of Human Glioblastoma Multiforme

Shiva Kazerounian
Associate Director of in Vivo Pharmacology
Berg Health

Eric Ibsen
Chief Executive Officer
Studylog